ANB033 targets CD122 to block the IL‑15 and IL‑2 signals that drive the pathogenic immune cells responsible for intestinal damage in celiac disease.
Celiac disease is marked by a dense infiltration of inflammatory CD122+ immune cells, including:
CD122+ cells increased 50–150% compared to healthy tissue. In addition, epithelial cells, myeloid cells, and lymphocytes broadly expressed IL‑15, fueling persistent inflammation.
Excessive IL‑15 and IL‑2 signaling drives pathogenic immune activation in celiac disease. ANB033 blocks CD122, the shared receptor subunit for both cytokines, enabling upstream modulation of disease-driving cells.
IL-2 stimulates
Inhibiting IL-2 signaling reduces